Loading clinical trials...

Escitalopram in Patients With Generalized Anxiety Disorder | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Escitalopram in Patients With Generalized Anxiety Disorder

Efficacy and Safety of Escitalopram in Patients With Generalized Anxiety Disorder; Open-label, One Arm Postmarketing Study in Russia

NCT00902564•H. Lundbeck A/S

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the effect of escitalopram after 8 weeks of treatment in patients with Generalized Anxiety Disorder (GAD), to evaluate proportion of patients who respond to escitalopram during the treatment period, and to evaluate safety of escitalopram.

Detailed Description

The study will be performed in Russia, as an open-label, uncontrolled, one arm trial. The patients will receive escitalopram for 8 weeks. Start and maintenance dosages as well as dose titration will be left to the investigators' decision (5 to 20 mg/day), in accordance with the national Summary of Products Characteristics (SPC).

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•The patient suffers from GAD, diagnosed according to ICD-10 (International Classification of Diseases)
•The patient meets criteria as set out in the national SPC for escitalopram
•The patient is, in the opinion of the investigator, otherwise healthy on the basis of a physical examination, medical history and vital signs

Exclusion Criteria

•The patient has/has had an alcohol or drug abuse-related disorder, as defined in ICD-10
•The patient has contraindications to escitalopram
•The patient has a history of severe drug allergy or hypersensitivity, or known hypersensitivity to escitalopram
•The patient has a serious illness and/or serious sequelae thereof, including liver or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, or metabolic disturbance
•The patient is pregnant or breast-feeding
•The patient, if a woman of childbearing potential, is not using adequate contraception

Locations (1)

RU001

Moscow, Russia

Key Dates

Start Date

March 1, 2009

Primary Completion Date

December 1, 2009

Completion Date

March 1, 2010

Last Updated

June 10, 2011

Enrollment

ACTUAL participants

Conditions

Generalized Anxiety Disorder

Interventions

Escitalopram

DRUG

Transcranial Alternating Current Stimulation for Generalized Anxiety Disorder and Insomnia: An Open-Label Pilot Study

NCT07429578

Generalized Anxiety Disorder (GAD)Chronic Insomnia

View study

RECRUITINGNA

Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders

NCT06661460

ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)Specific Phobia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 10, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Escitalopram in Patients With Generalized Anxiety Disorder

Inclusion Criteria

Exclusion Criteria

Transcranial Alternating Current Stimulation for Generalized Anxiety Disorder and Insomnia: An Open-Label Pilot Study

Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder

Teletherapy vs. In-Person Cognitive Behavioral Therapy for Generalized Anxiety Disorder

Electroclinical Correlation of Anxiety